Article
Methotrexate and Pralatrexate
1 Aug 2015
Abstract excerpt
This article reviews methotrexate and the more potent, related compound, pralatrexate, for the treatment of cutaneous T-cell lymphomas, including mycosis fungoides, Sézary syndrome, and CD30+ lymphoproliferative disorders. Although these folate antagonists are traditionally viewed as antiproliferative cell cycle inhibitors, it is recognized that they inhibit DNA methylation, providing a rationale for their use as...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
